Hemochromatosis and Iron Overload Screening Study (HEIRS)

Note that you will be prompted to log in or register an account

Accession Number
HLB00690919a

Study Type
Epidemiology Study

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
January 2000 - January 2006

NHLBI Division
DCVS

Dataset(s) Last Updated
May 3, 2019

Primary Publication URLs
N/A

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research Yes

Commercial Use Specimen Restrictions No

Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes

Genetic Use Of Specimens Allowed? Yes

Genetic Use Area Of Research Restrictions Yes

Specific Consent Restrictions
Use of biospecimens and data is generally restricted to iron-related and hereditary hemochromatosis studies. A subset of biospecimens and data are available for broader use.

Objectives

The HEIRS Study evaluated the prevalence and genetic and environmental determinants and potential clinical, personal, and societal impact of iron overload and hereditary hemochromatosis in a multi-center, multiethnic, primary care-based sample of adults.

Background

Hereditary iron overload, or hemochromatosis, is a common inherited disorder resulting from overabsorption of dietary iron. Excess iron is deposited in body tissues, and can accumulate to toxic levels over time causing damage in multiple organ systems. If untreated, these conditions may lead to death. Evidence suggests that early diagnosis and treatment can prevent disease manifestations and enable normal life expectancy. Thus, hemochromatosis may be suitable for detection and intervention through primary care screening strategies; however, much remains to be learned about the penetrance and expression of the known gene variants, HFE C282Y and H63D, associated with hemochromatosis. Iron overload and hereditary hemochromatosis have not been as extensively studied in racial/ethnic groups other than Caucasians.

Participants

The initial screen phase included 102,000 adults recruited over a 2-year period from 5 North American Field Centers (approx. 51% white, 24% African American, 11% Asian, 11% Hispanic, and 3% unidentified race; 63% are female and 37% are male).

Design

During the initial screen phase in 2001-2002, participants were recruited from primary care practices and blood-drawing laboratories. Blood specimens were tested for transferrin saturation (TS), serum ferritin (SF), and HFE C282Y and H63D genetic variants. Before genetic screening, participants were asked whether they had a history of medical conditions related to iron overload. Those participants with elevated iron levels and/or C282Y homozygosity, their family members, and frequency-matched control participants completed an examination that obtained data on personal and family medical history, lifestyle characteristics, genetic counseling and assessment of ethical, legal and social implications of screening, as well as clinical and biochemical measures. A separate randomized study examined the acceptability of genotypic or phenotypic (biochemical) screening for hemochromatosis.

The majority of HEIRS participants have a consent limited to research on iron related disorders; however, specimens and data from ~6770 participants are available for broader research use.

Conclusions

Findings include: 1) transferrin saturation (TS) and serum ferritin (SF) mean levels differ across race/ethnic groups; 2) HFE C282Y variant does not account for these levels in non-Caucasians (Adams et al, NEJM 352:1769-78, 2005); and 3) there is similar participant acceptance for genotypic as for phenotypic testing (Anderson et al, Genet Med. 7:557-63, 2005).

Additional Details

Subjects:

Cases: 1678

Controls: 641

Screened Only: 99623

Age:

 

Screened Only

Case

Control

All

N

%

N

%

N

%

N

%

Missing

123

0.12

.

.

.

.

123

0.12

25-29

7209

7.24

62

3.69

29

4.52

7300

7.16

30-34

8734

8.77

90

5.36

30

4.68

8854

8.69

35-39

9771

9.81

120

7.15

44

6.86

9935

9.75

40-44

11265

11.31

153

9.12

50

7.80

11468

11.25

45-49

12397

12.44

218

12.99

89

13.88

12704

12.46

50-54

12580

12.63

258

15.38

83

12.95

12921

12.67

55-59

10789

10.83

211

12.57

87

13.57

11087

10.88

60-64

9099

9.13

192

11.44

61

9.52

9352

9.17

65-69

6860

6.89

158

9.42

69

10.76

7087

6.95

70-74

5049

5.07

97

5.78

47

7.33

5193

5.09

75-79

3413

3.43

77

4.59

32

4.99

3522

3.45

80-84

1676

1.68

33

1.97

17

2.65

1726

1.69

85-89

506

0.51

9

0.54

2

0.31

517

0.51

90

152

0.15

.

.

1

0.16

153

0.15

Sex:
 

 

Screened Only

Case

Control

All

N

%

N

%

N

%

N

%

Missing

12

0.01

.

.

.

.

12

0.01

Male

36686

36.82

930

55.42

240

37.44

37856

37.13

Female

62925

63.16

748

44.58

401

62.56

64074

62.85

Race:

 

Screened Only

Case

Control

All

N

%

N

%

N

%

N

%

Hispanic

12682

12.73

126

7.51

56

8.74

12864

12.62

Asian/Pacific Islander

13301

13.35

466

27.77

111

17.32

13878

13.61

African American

27154

27.26

288

17.16

92

14.35

27534

27.01

Caucasian

43907

44.07

762

45.41

367

57.25

45036

44.18

Other

2579

2.59

36

2.15

15

2.34

2630

2.58

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Visits (Vials):

25 July 2023
 

Serum Plasma Lymphocytes DNA Buffy Coat Dried Buffy Coat Total
Screening 76,253 10 18 2,831 73,227 80,386 232,725
Comprehensive Clinical Exam 11,192 4,578 7,968 20,559 2 2 44,301
Visits (Subjects):
25 July 2023
 
Serum
Total number of subjects Average volume (ml) per subject
Screening 71,930 0.55
Comprehensive Clinical Exam 2,237 2.91
 
  Plasma
Total number of subjects Average volume (ml) per subject
Screening 5 1.00
Comprehensive Clinical Exam 2,225 1.21
 
  Lymphocytes
Total number of subjects Average vials per subject
Screening 5 3.60
Comprehensive Clinical Exam 2,208 3.61
  Buffy Coat
Total number of subjects Average vials per subject
Screening 71,518 1.02
Comprehensive Clinical Exam 2 1.00
 
  Dried Buffy Coat
Total number of subjects Average vials per subject
Screening 78,627 1.02
Comprehensive Clinical Exam 2 1.00
 
  DNA
Total number of subjects Average mass (µg) per subject Average vials per subject
Screening 1,975 110.31 1.43
Comprehensive Clinical Exam 2,233 318.85 9.21

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens and Study Datasets

Materials Available

  • Buffy Coat
  • DNA
  • Dried Buffy Coat
  • Lymphocytes
  • Plasma
  • Serum
  • More Details

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.